VanEck Pharmaceutical ETF (PPH) Short Interest Ratio & Short Volume $82.58 -1.26 (-1.50%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$82.76 +0.18 (+0.22%) As of 08/7/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock VanEck Pharmaceutical ETF Short Interest DataVanEck Pharmaceutical ETF (PPH) has a short interest of 2.57 million shares, representing 41.19% of the float (the number of shares available for trading by the public). This marks a -9.82% decrease in short interest from the previous month. The short interest ratio (days to cover) is 9.9, indicating that it would take 9.9 days of the average trading volume of 405,991 shares to cover all short positions.Current Short Interest2,570,000 sharesPrevious Short Interest2,850,000 sharesChange Vs. Previous Month-9.82%Dollar Volume Sold Short$225.88 millionShort Interest Ratio9.9 Days to CoverLast Record DateFebruary 15, 2025Outstanding Shares5,440,000 sharesShort Percent of Float41.19%Today's Trading Volume338,536 sharesAverage Trading Volume405,991 sharesToday's Volume Vs. Average83% Short Selling VanEck Pharmaceutical ETF? Sign up to receive the latest short interest report for VanEck Pharmaceutical ETF and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPPH Short Interest Over TimePPH Days to Cover Over TimePPH Percentage of Float Shorted Over Time VanEck Pharmaceutical ETF Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/15/20252,570,000 shares $225.88 million -9.8%41.2%9.9 $87.89 1/31/20252,850,000 shares $253.42 million -14.4%N/A11.6 $88.92 1/15/20253,330,000 shares $285.05 million +33.2%N/A15.1 $85.60 12/31/20242,500,000 shares $215.70 million -3.1%N/A12.9 $86.28 12/15/20242,580,000 shares $226.58 million -1.2%N/A13.7 $87.82 11/30/20242,610,000 shares $235.27 million +10.6%N/A14.1 $90.14 11/15/20242,360,000 shares $204.35 million +26.9%N/A12.1 $86.59 10/31/20241,860,000 shares $169.84 million +8.1%N/A11 $91.31 10/15/20241,720,000 shares $162.80 million -8.0%N/A11.6 $94.65 9/30/20241,870,000 shares $177.71 million -0.5%N/A12.8 $95.03 Get the Latest News and Ratings for PPH and Related StocksEnter your email address below to receive the latest news and analysts' ratings for VanEck Pharmaceutical ETF and its competitors with MarketBeat's FREE daily newsletter. 9/15/20241,880,000 shares $183.34 million -4.6%N/A13.9 $97.52 8/31/20241,970,000 shares $195.88 million +18.0%N/A14 $99.43 8/15/20241,670,000 shares $160.64 million -17.3%N/A11.8 $96.19 7/31/20242,020,000 shares $188.02 million +27.9%N/A14.8 $93.08 7/15/20241,580,000 shares $146.91 million +10.5%N/A10.8 $92.98 6/30/20241,430,000 shares $130.82 million +3.6%N/A9.7 $91.48 6/15/20241,380,000 shares $126.52 million -2.8%N/A9.2 $91.68 5/31/20241,420,000 shares $128.45 million +22.4%N/A9.5 $90.46 5/15/20241,160,000 shares $105.22 million -19.4%N/A8.2 $90.71 4/30/20241,440,000 shares $126.09 million +2.9%N/A9.5 $87.56 4/15/20241,400,000 shares $119.62 million -11.4%N/A11.3 $85.44 3/31/20248,700 shares $789.09 thousand -99.5%N/A0.1 $90.70 3/15/20241,570,000 shares $140.59 million -8.7%N/A13 $89.55 2/29/20241,720,000 shares $152.74 million +5.5%N/A14.9 $88.80 2/15/20241,630,000 shares $144.16 million -22.4%N/A14.9 $88.44 1/31/20242,100,000 shares $179.13 million -0.5%N/A18.6 $85.30 1/15/20242,110,000 shares $180.57 million +14.7%N/A19.3 $85.58 12/31/20231,840,000 shares $149.71 million -4.7%N/A16.5 $81.37 12/15/20231,930,000 shares $152.10 million -18.9%N/A18 $78.81 11/30/20232,380,000 shares $186.85 million -1.2%N/A21.7 $78.51 11/15/20232,410,000 shares $184.75 million +4.3%N/A20.9 $76.66 10/31/20232,310,000 shares $173.97 million +4.5%N/A18.7 $75.31 10/15/20232,210,000 shares $177.00 million -1.3%N/A17.3 $80.09 9/30/20232,240,000 shares $178.89 million -1.3%N/A17.2 $79.86 9/15/20232,270,000 shares $186.03 million -2.6%N/A16.7 $81.95 8/31/20232,330,000 shares $190.83 million +16.5%N/A17.2 $81.90 8/15/20232,000,000 shares $165.46 million -17.0%N/A15.6 $82.73 7/31/20232,410,000 shares $193.81 million -0.4%N/A19.2 $80.42 7/15/20232,420,000 shares $188.49 million +5.2%N/A20.7 $77.89 6/30/20232,300,000 shares $181.17 million +0.4%N/A20.1 $78.77Altucher: Trump’s Great Gain is starting (Ad)New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.See Altucher’s Trump crypto prediction here 6/15/20232,290,000 shares $179.70 million +19.9%N/A21.6 $78.47 5/31/20231,910,000 shares $144.49 million -12.8%N/A16.6 $75.65 5/15/20232,190,000 shares $172.48 million -10.3%N/A16.7 $78.76 4/30/20232,440,000 shares $192.44 million +1.2%N/A17.7 $78.87 4/15/20232,410,000 shares $191.59 million +3.9%N/A14.3 $79.50 3/31/20232,320,000 shares $180.10 million +19.0%N/A14.4 $77.63 3/15/20231,950,000 shares $144.65 million -18.8%N/A12.1 $74.18 2/28/20232,400,000 shares $181.56 million +8.1%N/A15.1 $75.65 2/15/20232,220,000 shares $173.74 million -7.5%N/A15.4 $78.26 1/31/20232,400,000 shares $188.02 million -0.4%N/A16.8 $78.34 1/15/20232,410,000 shares $191.60 million +4.8%N/A17.1 $79.50 12/30/20222,300,000 shares $178.80 million -3.8%N/A18.4 $77.74 12/15/20222,390,000 shares $186.68 million +7.2%N/A16 $78.11 11/30/20222,230,000 shares $171.78 million +10.4%N/A14.5 $77.03 11/15/20222,020,000 shares $147.97 million +27.9%N/A12.5 $73.25 10/31/20221,580,000 shares $115.10 million +6.8%N/A10.1 $72.85 10/15/20221,480,000 shares $101.05 million No ChangeN/A8.8 $68.28 9/30/20222,150,000 shares $144.57 million +4.9%N/A13 $67.24 9/15/20222,050,000 shares $144.94 million -10.1%N/A13 $70.70 8/31/20222,280,000 shares $161.29 million +31.0%N/A12.7 $70.74 8/15/20221,740,000 shares $133.18 million +84.7%N/A9.3 $76.54 7/31/2022942,200 shares $72.46 million +45.4%N/A5 $76.90 7/15/2022648,000 shares $49.53 million +12.5%N/A3.8 $76.43 6/30/2022576,100 shares $44.27 million -3.0%N/A3.2 $76.84 6/15/2022593,600 shares $43.62 million +55.3%N/A3.4 $73.49 5/31/2022382,200 shares $30.28 million +1.7%N/A2.7 $79.23 5/15/2022375,700 shares $28.66 million +10.4%N/A3.1 $76.29 4/30/2022340,400 shares $26.40 million -5.6%N/A2.5 $77.55 4/15/2022360,400 shares $29.47 million +25.1%N/A2.7 $81.76 3/31/2022288,100 shares $22.98 million +3.3%N/A2.5 $79.76 3/15/2022279,000 shares $21.28 million +2.2%N/A2.9 $76.28 2/28/2022272,900 shares $20.66 million -6.0%N/A3.1 $75.71 2/15/2022290,300 shares $22.30 million +86.0%N/A3.5 $76.81 1/31/2022156,100 shares $11.84 million +14.7%N/A2.1 $75.85 1/15/2022136,100 shares $10.49 million -29.7%N/A3.1 $77.04 12/31/2021193,500 shares $14.89 million -12.0%N/A4.8 $76.96 12/15/2021219,900 shares $16.53 million +7.3%N/A6.2 $75.19 11/30/2021205,000 shares $14.64 million +0.5%N/A5.9 $71.43 11/15/2021203,900 shares $15.44 million -28.1%N/A6.1 $75.74 10/29/2021283,400 shares $21.30 million -5.6%N/A8.7 $75.15 10/15/2021300,200 shares $21.90 million +0.1%N/A8.8 $72.94 9/30/2021300,000 shares $21.85 million +19.2%N/A5.5 $72.82 9/15/2021251,600 shares $18.58 million +89.7%N/A4.9 $73.83 8/31/2021132,600 shares $10.08 million +2.7%N/A2.8 $76.04 8/13/2021129,100 shares $9.81 million -38.8%N/A2.6 $76.01 7/30/2021211,000 shares $15.80 million -11.6%N/A3.7 $74.86 7/15/2021238,800 shares $17.38 million -14.5%N/A2.6 $72.78 6/30/2021279,400 shares $20.41 million +13.6%N/A2.8 $73.06 6/15/2021245,900 shares $18.29 million +23.8%N/A2.5 $74.36 5/28/2021198,700 shares $14.34 million -20.5%N/A1.5 $72.15Altucher: Trump’s Great Gain is starting (Ad)New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.See Altucher’s Trump crypto prediction here 5/14/2021250,000 shares $17.94 million +22.6%N/A1.7 $71.76 4/30/2021204,000 shares $14.25 million -89.3%N/A1.4 $69.87 4/15/20211,910,000 shares $130.30 million +0.5%N/A17.4 $68.22 3/31/20211,900,000 shares $130.91 million +124.6%N/A21.1 $68.90 3/15/2021845,800 shares $58.23 million +102.7%N/A9 $68.85 2/26/2021417,200 shares $28.36 million +22.2%N/A6.7 $67.99 2/12/2021341,300 shares $23.79 million +342.7%N/A7 $69.71 1/29/202177,100 shares $5.35 million -59.3%N/A1.8 $69.34 1/15/2021189,300 shares $13.13 million +22.7%N/A3.3 $69.38 12/31/2020154,300 shares $10.19 million -22.3%N/A2.3 $66.03 12/15/2020198,600 shares $12.97 million +24.7%N/A3.2 $65.29 11/30/2020159,300 shares $10.41 million -7.1%N/A2.3 $65.35 11/15/2020171,500 shares $11.22 million -24.4%N/A2.5 $65.40 10/30/2020226,800 shares $13.41 million -63.9%N/A3.2 $59.11 10/15/2020628,600 shares $39.61 million -4.1%N/A0 $63.02 9/30/2020655,400 shares $40.75 million +195.8%N/A14.5 $62.17 9/15/2020681,900 shares $42.97 million +207.7%N/A15.2 $63.01 8/31/2020221,600 shares $14.30 million -8.2%N/A6.5 $64.53 8/14/2020241,300 shares $15.50 million +18.4%N/A7.8 $64.22 PPH Short Interest - Frequently Asked Questions What is VanEck Pharmaceutical ETF's current short interest? Short interest is the volume of VanEck Pharmaceutical ETF shares that have been sold short but have not yet been covered or closed out. As of February 15th, traders have sold 2,570,000 shares of PPH short. 41.19% of VanEck Pharmaceutical ETF's shares are currently sold short. Learn More on VanEck Pharmaceutical ETF's current short interest. What is a good short interest ratio for VanEck Pharmaceutical ETF? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PPH shares currently have a short interest ratio of 10.0. Learn More on VanEck Pharmaceutical ETF's short interest ratio. Which institutional investors are shorting VanEck Pharmaceutical ETF? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of VanEck Pharmaceutical ETF: Jane Street Group LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for VanEck Pharmaceutical ETF? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 41.19% of VanEck Pharmaceutical ETF's floating shares are currently sold short. Is VanEck Pharmaceutical ETF's short interest increasing or decreasing? VanEck Pharmaceutical ETF saw a drop in short interest in February. As of February 15th, there was short interest totaling 2,570,000 shares, a drop of 9.8% from the previous total of 2,850,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does VanEck Pharmaceutical ETF's short interest compare to its competitors? 41.19% of VanEck Pharmaceutical ETF's shares are currently sold short. Here is how the short interest of companies compare to VanEck Pharmaceutical ETF: VanEck Biotech ETF (0.27%), Invesco Dorsey Wright Healthcare Momentum ETF (0.26%), ProShares Ultra Nasdaq Biotechnology (1.16%), Invesco Nasdaq Biotechnology ETF (0.41%), First Trust Nasdaq Pharmaceuticals ETF (0.36%), JPMorgan Healthcare Leaders ETF (0.07%), ProShares UltraShort Nasdaq Biotechnology (5.41%), and iShares Biotechnology ETF (29.39%). Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($25.81 billion), iShares 20+ Year Treasury Bond ETF ($10.38 billion), MicroStrategy Incorporated ($7.74 billion), AppLovin Corporation ($6.32 billion), Apollo Global Management Inc. ($5.97 billion), Super Micro Computer, Inc. ($4.89 billion), Charter Communications, Inc. ($4.52 billion), Capital One Financial Corporation ($3.94 billion), Schlumberger Limited ($3.19 billion), and Reddit Inc. ($3.01 billion). View all of the most shorted stocks. What does it mean to sell short VanEck Pharmaceutical ETF stock? Short selling PPH is an investing strategy that aims to generate trading profit from VanEck Pharmaceutical ETF as its price is falling. PPH shares are trading down $1.26 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against VanEck Pharmaceutical ETF? A short squeeze for VanEck Pharmaceutical ETF occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PPH, which in turn drives the price of the stock up even further. How often is VanEck Pharmaceutical ETF's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PPH, twice per month. The most recent reporting period available is February, 15 2025. More Short Interest Resources from MarketBeat Related Companies BBH Short Interest Data PTH Short Interest Data BIB Short Interest Data IBBQ Short Interest Data FTXH Short Interest Data JDOC Short Interest Data BIS Short Interest Data IBB Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PPH) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VanEck Pharmaceutical ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share VanEck Pharmaceutical ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
